EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Efficacy of Etrasimod in Ulcerative Colitis: Analysis of ELEVATE UC 52 and ELEVATE UC 12 by Baseline Endoscopic Severity

Andres J Yarur, Walter Reinisch, Shannon Chang, Krisztina B Gecse, Jesse Green, Arcangelo M Abbatemarco, Joseph Wu, Martina Goetsch, Krisztina Lazin, Gokul Pradeep, Bruce E Sands

Clinical Gastroenterology and Hepatology · 2026-01 · 24 (1) · 210-220.e3

DOI: 10.1016/j.cgh.2025.06.020 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-01. Verfasst von Andres J Yarur und 10 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Bowel Disease Center and Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis. In this post hoc analysis, induction and maintenance efficacy of etrasimod 2 mg versus placebo were assessed by baseline Mayo endoscopic subscore in ELEVATE UC 52 and ELEVATE UC 12. METHODS: Moderate and severe endoscopic disease were defined as a centrally read endoscopic subscore of 2 and 3, respectively. Efficacy end points were evaluated at Weeks 12 (pooled population) and 52 (ELEVATE UC 52). Subgroup analyses were stratified by baseline modified Mayo score (4-6 vs 7-9) and prior biologic/Janus kinase inhibitor exposure. RESULTS: Overall, 235 patients with moderate and 292 with severe endoscopic disease received etrasimod; 112 and 148 patients, respectively, received placebo. At both time points, significantly greater proportions of patients receiving etrasimod compared with placebo achieved clinical remission in the moderate (Week 12: 38.3% vs 17.9%; Week 52: 36.5% vs 14.3%; both P < .001) and severe (Week 12: 18.2% vs 6.1%; Week 52: 29.4% vs 3.4%; both P < .001) endoscopic disease subgroups. Similar efficacy was observed at Weeks 12 and 52 for most end points. The proportion of etrasimod-treated patients with severe endoscopic disease achieving end points was generally numerically higher at Week 52 versus Week 12, relative to placebo. Subgroup analysis findings were generally similar. CONCLUSIONS: Etrasimod demonstrated significant induction and maintenance efficacy over placebo in both moderate and severe endoscopic disease. Response to etrasimod in patients with severe endoscopic disease may continue to improve beyond 12-week induction therapy (ClinicalTrials.gov: NCT03945188; NCT03996369).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHumansMaleFemaleMiddle AgedAdultSeverity of Illness IndexTreatment OutcomeDouble-Blind MethodAgedPlacebos

Stichwörter der Autor:innen

Disease SeverityEndoscopic SubscoreEtrasimodSphingosine 1-Phosphate Receptor ModulatorUlcerative Colitis

Substanzen

Placebos

Autor:innen und Institutionen

  • Inflammatory Bowel Disease Center and Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California.
  • Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Division of Gastroenterology and Hepatology, New York University Langone Health, New York, New York.
  • Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Pfizer Inc, Collegeville, Pennsylvania. Electronic address: Jesse.Green@pfizer.com.
  • Pfizer Inc, New York, New York.

Förderung

  • Pfizer

Zitieren

APA

Yarur, A. J., Reinisch, W., Chang, S., Gecse, K. B., Green, J., Abbatemarco, A. M., Wu, J., Goetsch, M., Lazin, K., Pradeep, G., & Sands, B. E. (2026). Efficacy of Etrasimod in Ulcerative Colitis: Analysis of ELEVATE UC 52 and ELEVATE UC 12 by Baseline Endoscopic Severity. Clinical Gastroenterology and Hepatology, 24(1), 210-220.e3. https://doi.org/10.1016/j.cgh.2025.06.020

Vancouver

Yarur AJ, Reinisch W, Chang S, Gecse KB, Green J, Abbatemarco AM, et al. Efficacy of Etrasimod in Ulcerative Colitis: Analysis of ELEVATE UC 52 and ELEVATE UC 12 by Baseline Endoscopic Severity. Clinical Gastroenterology and Hepatology. 2026;24(1):210-220.e3. doi:10.1016/j.cgh.2025.06.020

BibTeX
@article{Yarur2026,
  author = {Yarur, Andres J and Reinisch, Walter and Chang, Shannon and Gecse, Krisztina B and Green, Jesse and Abbatemarco, Arcangelo M and Wu, Joseph and Goetsch, Martina and Lazin, Krisztina and Pradeep, Gokul and Sands, Bruce E},
  title = {Efficacy of Etrasimod in Ulcerative Colitis: Analysis of ELEVATE UC 52 and ELEVATE UC 12 by Baseline Endoscopic Severity},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {1},
  pages = {210--220.e3},
  doi = {10.1016/j.cgh.2025.06.020}
}
Kostenlos starten →